<DOC>
	<DOC>NCT00833963</DOC>
	<brief_summary>The MotHER Pregnancy Registry is a U.S.-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with herceptin plus perjeta with or without pertuzumab, or ado-trastuzumab emtansine, during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).</brief_summary>
	<brief_title>An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Pregnant; women identified at any trimester of pregnancy may enroll in this study as long as enrollment occurs prior to experiencing pregnancy outcome Exposure to at least one dose of trastuzumab (as adjuvant or metastatic treatment), pertuzumab plus trastuzumab combination treatment, or adotrastuzumab emtansine during pregnancy or within 7 months prior to conception United States resident Patient has provided verbal or written informed consent (on her own behalf and on behalf of her child) Prior knowledge of pregnancy outcome at time of enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Herceptin</keyword>
	<keyword>MBC</keyword>
	<keyword>BC</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>childbirth</keyword>
	<keyword>Perjeta</keyword>
	<keyword>Kadcyla</keyword>
	<keyword>pertuzumab</keyword>
	<keyword>ado-trastuzumab emtansine</keyword>
</DOC>